ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag intellectual property disease medicine evolution

Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017 | 10 min read
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Illustration of DNA
Can “Gene Writing” Deliver What Gene Editing Can’t?
Dan Robitzski | Dec 12, 2022 | 10+ min read
A biotech startup called Tessera Therapeutics has made a splash with its claims about the trademarked technology. Is the excitement justified?
dual expresser t cell immunology type 1 diabetes
The Science News that Shaped 2019
Kerry Grens | Dec 20, 2019 | 6 min read
A T cell discovery, “hachimoji” DNA, a new species of human, and mounting fears of espionage rounded off the list this year.
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
Week in Review: March 27–31
Tracy Vence | Mar 31, 2017 | 3 min read
European Patent Office greenlights CRISPR patent; scientists reconsider a cancer drug target; NIH accepts preprints in grant applications; MERS drug developers test antibodies; experts weigh the risks and benefits of whole-exome sequencing for healthy people
Why Pharma Must Go Hollywood
Liam Bernal | Feb 1, 2007 | 10+ min read
WHY PHARMA MUST GO HOLLYWOOD The answer to stagnating R&D can be found in the creativity of the movie industry.By Liam Bernal The pharmaceutical industry should be a tangible demonstration of the value of the scientific enterprise. Enormous benefits to society should, and generally do, flow from a healthy pharma sector. The transformation of AIDS into a treatable chronic disease is an examp
Week in Review: April 6–10
Tracy Vence | Apr 9, 2015 | 3 min read
CRISPR patents; contagious clam cancer; modeling cancer-linked cachexia; investigating immune response to Ebola
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
Of Cells and Limits
Anna Azvolinsky | Mar 1, 2015 | 9 min read
Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.
How to Create a Successful Fish Tale?
A. J. S. Rayl | Aug 19, 2001 | 10+ min read
More than 80 percent of the planet's living organisms exist only in aquatic ecosystems. Some may harbor secrets to human origins, and clues, treatments--perhaps even cures--for human disease. Some are critical bioindicators that portend the health of the biosphere. Yet, overall, scientists know little about the biochemical processes of these life forms. The vast, rich knowledge within the oceans and freshwater systems on Earth remains virtually untapped, because in the world of biological resear

Run a Search

ADVERTISEMENT